Literature DB >> 29661023

TAK1 mediates apoptosis via p38 involve in ischemia-induced renal fibrosis.

Jun Zhou1, Jiying Zhong1, Zhenxing Huang1, Meijuan Liao1, Sen Lin1, Jia Chen1, Hongtao Chen2.   

Abstract

Renal fibrosis is a common and characteristic symptom of chronic kidney disease (CKD). However, the molecular mechanisms of renal fibrosis remain elusive. Ischemia injury, as a major cause of AKI, deserves more attention in order to improve the knowledge of AKI-induced fibrosis. Transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) interacts directly with TGF-β, which play a critical role in the progression of fibrosis. Therefore, the present study aimed to investigate the role of TAK1 in the pathogenesis of ischemia-induced renal fibrosis. Compared with mice in the vehicle group, mice intraperitoneally injected with TAK1 inhibitor were found to have lower serum creatinine, less tubular damage and more mild fibrosis following ischemia-induced AKI. Furthermore, inhibition of TAK1 reduced p38 phosphorylation, decreased expression of Bax and caspase 3 and apoptosis cells in kidneys of mice treated with IR-induced AKI. Compared with vehicle-treated renal tubular epithelial cells, TAK1 overexpression cells were found to have a higher apoptosis and fibrosis index level and p38 phosphorylation following hypoxia/reoxygenation (H/R) treatment. Furthermore, the p38 inhibitor combined with TAK1 overexpression verified the role of TAK1/p38 signaling pathway in apoptosis and fibrosis index level of renal tubular epithelial cells treated with H/R. Thus, our results show that TAK1 plays an important role in the pathogenesis of ischemia-induced renal fibrosis and may mediate p38-regulated cell apoptosis.

Entities:  

Keywords:  Renal; TAK1; fibrosis; ischemia; p38

Mesh:

Substances:

Year:  2018        PMID: 29661023     DOI: 10.1080/21691401.2018.1442841

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  6 in total

Review 1.  RIPK3: A New Player in Renal Fibrosis.

Authors:  Ying Shi; Xinming Chen; Chunling Huang; Carol Pollock
Journal:  Front Cell Dev Biol       Date:  2020-06-16

2.  Paclitaxel induces apoptosis through the TAK1-JNK activation pathway.

Authors:  Di Yu-Wei; Zhuo-Sheng Li; Shu-Min Xiong; Ge Huang; Yan-Fei Luo; Tie-Ying Huo; Mao-Hua Zhou; You-Wei Zheng
Journal:  FEBS Open Bio       Date:  2020-07-31       Impact factor: 2.693

3.  CARD3 Promotes Cerebral Ischemia-Reperfusion Injury Via Activation of TAK1.

Authors:  Xiaolin Wu; Lijin Lin; Juan-Juan Qin; Lifen Wang; Hao Wang; Yichun Zou; Xueyong Zhu; Ying Hong; Yan Zhang; Ye Liu; Can Xin; Shuangxiang Xu; Shengda Ye; Jianjian Zhang; Zhongwei Xiong; Lihua Zhu; Hongliang Li; Jincao Chen; Zhi-Gang She
Journal:  J Am Heart Assoc       Date:  2020-04-30       Impact factor: 5.501

4.  TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy.

Authors:  Dengqiu Xu; Sijia Li; Lu Wang; Jingwei Jiang; Lei Zhao; Xiaofei Huang; Zeren Sun; Chunjie Li; Lixin Sun; Xihua Li; Zhenzhou Jiang; Luyong Zhang
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-11-25       Impact factor: 12.910

Review 5.  Recent Advances in Diabetic Kidney Diseases: From Kidney Injury to Kidney Fibrosis.

Authors:  Peir-Haur Hung; Yung-Chien Hsu; Tsung-Hsien Chen; Chun-Liang Lin
Journal:  Int J Mol Sci       Date:  2021-11-01       Impact factor: 5.923

6.  A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.

Authors:  Dengqiu Xu; Lei Zhao; Jingwei Jiang; Sijia Li; Zeren Sun; Xiaofei Huang; Chunjie Li; Tao Wang; Lixin Sun; Xihua Li; Zhenzhou Jiang; Luyong Zhang
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-08-31       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.